Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dapansutrile · OLT-1177

Small molecule · Inhibitor of NLRP3 inflammasome sensor (NLRP3) (NLRP3) · developed by Olatec Therapeutics

Phase 1/2 Most advanced trial

What is Dapansutrile?

Dapansutrile is an orally bioavailable small molecule that specifically binds to and inhibits NLRP3, the sensor of the NLRP3 inflammasome, preventing its formation. This reduces production of the pro-inflammatory cytokines IL-1beta and IL-18. It is being studied in melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
OLT-1177
Drug type
Small molecule
Targets
NLRP3 inflammasome sensor (NLRP3) (NLRP3)
Mechanism
Inhibitor of NLRP3 inflammasome sensor (NLRP3) (NLRP3)
Pathways
NLRP3 inflammasome formation, IL-1beta and IL-18 production
Therapy area
Oncology
Developer
Olatec Therapeutics, Inc.
In trials of
MRK
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
2Z03364G96

Conditions studied

Melanoma

Other drugs acting on NLRP3

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.